TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10464783

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/die)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion in 4 patients
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 14
Study: 7598013

Group type: EXPERIMENTAL
Intervention: Reducing dietary saturated fat
Number of subjects: 0

Group type: COMPARATOR
Intervention: High carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High monounsaturated fat diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Specific saturated fatty acids
Number of subjects: 0
Study: 2142294

Group type: EXPERIMENTAL
Intervention: BN 52063 240 mg p.o. 3 hours before exercise challenge
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BN 52063 5 mg by inhalation 30 minutes before exercise challenge
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 349439

Group type: EXPERIMENTAL
Intervention: Quinestrol 2 mg single dose
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Tace 72 mg every 12 hours for 2 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 7115012

Group type: EXPERIMENTAL
Intervention: imipramine hydrochloride, 150 mg daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: amitriptyline hydrochloride, 150 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (pretreatment HPA variables)
Number of subjects: 28
Study: 30727721

Group type: EXPERIMENTAL
Intervention: Topotecan (1.75 mg/m2 IV) and gemcitabine (starting dose 700 mg/m2 with increments of 100 mg/m2) administered on days 1, 8, and 15 every 28 days.
Number of subjects: 24
Study: 30504736

Group type: EXPERIMENTAL
Intervention: Aspirin therapy (80–325 mg)
Number of subjects: 5000
Study: 26900146

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mcg subcutaneously daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination of Teriparatide and Denosumab
Number of subjects: 94
Study: 25485672

Group type: EXPERIMENTAL
Intervention: Family Foundations intervention group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 22267762

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 38
Study: 19827506

Group type: EXPERIMENTAL
Intervention: Moist heat pack
Number of subjects: 18

Group type: COMPARATOR
Intervention: No heat pack
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dry nonheated heat pack
Number of subjects: 18
Study: 17970961

Group type: EXPERIMENTAL
Intervention: PCA parameters with T-end cursor moved backward and forward (+/- 8 ms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PCA parameters at long-term evaluation
Number of subjects: 30
Study: 16306738

Group type: EXPERIMENTAL
Intervention: Inguinal approach for obturator nerve block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pubic tubercle approach for obturator nerve block
Number of subjects: 50
Study: 11873026

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 459

Group type: COMPARATOR
Intervention: Intravenous meperidine analgesia
Number of subjects: 459
Study: 10448773

Group type: EXPERIMENTAL
Intervention: Inpatient Educational Program (IEP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 77
Study: 7598580

Group type: EXPERIMENTAL
Intervention: CPB perfusion temperature at 28 degrees C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPB perfusion temperature at 32 degrees C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPB perfusion temperature at 37 degrees C
Number of subjects: 30
Study: 2193511

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (n = 30)
Number of subjects: 60
Study: 627129

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (1.5 mg/kg)
Number of subjects: 6
Study: 31651183

Group type: EXPERIMENTAL
Intervention: CJDHWSWT plus eye drops systane ultra for 90 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nontreatment group (defined eye drops only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CJDHWSWT plus eye drops systane ultra
Number of subjects: 30
Study: 31349862

Group type: EXPERIMENTAL
Intervention: 300 mg daily aspirin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 29895406

Group type: EXPERIMENTAL
Intervention: SIT-ACT
Number of subjects: 14

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 14

Group type: COMPARATOR
Intervention: CONT-SIT
Number of subjects: 14
Study: 27023008

Group type: EXPERIMENTAL
Intervention: Bedtime glargine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Twice‐daily detemir
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 15
Study: 24563178

Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: aura-i
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fastrack
Number of subjects: 20
Study: 22608262

Group type: EXPERIMENTAL
Intervention: NovoTTF-100A (TTF)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Active chemotherapy
Number of subjects: 237
Study: 19174791

Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet for cow's milk, egg, and soy proteins for 8 weeks
Number of subjects: 33
Study: 17933738

Group type: EXPERIMENTAL
Intervention: Performance goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mastery goals or no goal
Number of subjects: 0
Study: 15893011

Group type: EXPERIMENTAL
Intervention: Topotecan (T) 1.0 mg/m2 d 1-5 and Cisplatin (DDP) 75 mg/m2 d 5 (arm A)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Topotecan (T) 1.5 mg/m2 d 1-3 and Cisplatin (DDP) 75 mg/m2 d 3 (arm B)
Number of subjects: 86
Study: 11826245

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (Nutropin, 1 mg/m2/day)
Number of subjects: 54
Study: 10194706

Group type: EXPERIMENTAL
Intervention: Dynamic MRI using a half-Fourier RARE sequence (imaging time 2 seconds)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dynamic MRI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cystourethrography
Number of subjects: 32

Group type: COMPARATOR
Intervention: Colpocystorectography
Number of subjects: 32
Study: 7786960

Group type: EXPERIMENTAL
Intervention: L-365,260, 30 mg qid
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 2394020

Group type: EXPERIMENTAL
Intervention: Presence of intra-epithelial haemorrhage shortly after myringotomy with grommet insertion
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Grommet in situ on follow-up 6 months later
Number of subjects: 92

Group type: COMPARATOR
Intervention: Absence of haemorrhage and grommet extrusion
Number of subjects: 92
Study: 375401

Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Butorphanol (4 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pentazocine (60 mg)
Number of subjects: 60
Study: 31680065

Group type: EXPERIMENTAL
Intervention: Hygieno-dietetic recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29134997

Group type: EXPERIMENTAL
Intervention: Photoexcitation and subsequent electronic energy relaxation and redistribution at low temperature (10 K) and room temperature (300 K)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Non‐radiative relaxation involving non‐adiabatic transitions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Excited state dynamics on a picosecond time‐scale
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intra-ring energy transfer
Number of subjects: 8
Study: 27884857

Group type: EXPERIMENTAL
Intervention: 1.5 hour online tutorial and a 3.5 hour skills building workshop in interprofessional shared decision-making (SDM)
Number of subjects: 0
Study: 24359265

Group type: EXPERIMENTAL
Intervention: Non-ablative 1550 nm erbium-glass FPS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ablative 10,600 nm CO2 FS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination therapy (FPS and CO2 FS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Treatment within 3 years of scar development
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Treatment >3 years after scar development
Number of subjects: 100
Study: 22357722

Group type: EXPERIMENTAL
Intervention: Restricted sleep (4 h/night)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Habitual sleep (9 h/night)
Number of subjects: 30
Study: 19789403

Group type: EXPERIMENTAL
Intervention: Hawthorn 450 mg twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 17514695

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1656
Study: 15140343

Group type: COMPARATOR
Intervention: Risedronate 5 mg daily
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Risedronate 50 mg once a week
Number of subjects: 1456
Study: 11453887

Group type: COMPARATOR
Intervention: Perindopril (4, 8, 16 mg) in HV; 4 mg in CHF patients
Number of subjects: 16
Study: 9743163

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 336 microg/d (4 puffs bid)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) 800 microg/d (4 puffs bid)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 339

Group type: COMPARATOR
Intervention: All treatment groups (BDP, TA, and placebo)
Number of subjects: 339
Study: 7532931

Group type: EXPERIMENTAL
Intervention: Curative resection (group 1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Palliative resection (group 2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Patients who did not undergo surgery (group 2)
Number of subjects: 49
Study: 3208513

Group type: EXPERIMENTAL
Intervention: RU 486 10 mg x 2 for seven days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: RU 486 25 mg x 2 for seven days
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: RU 486 50 mg x 2 for seven days
Number of subjects: 153
Study: 29925684

Group type: EXPERIMENTAL
Intervention: Intranasal carbetocin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 26837629

Group type: EXPERIMENTAL
Intervention: Internet diary modality
Number of subjects: 67

Group type: COMPARATOR
Intervention: Voice diary modality
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall diary participation
Number of subjects: 67
Study: 23755123

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 977

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 977
Study: 22533544

Group type: EXPERIMENTAL
Intervention: 24 weeks of cART
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 60 weeks of cART
Number of subjects: 112

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 112
Study: 20880120

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 3-week cycle with rituximab 375 mg/m² on day 1 (21 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bortezomib 1.6 mg/m² and rituximab on days 1, 8, 15, and 22 of a 5-week cycle (with rituximab given only in cycles 1 and 4) (21 patients)
Number of subjects: 42
Study: 18397330

Group type: EXPERIMENTAL
Intervention: Metronidazole for 5 days, 20 mg/kg/day for children and 1.5 g/day for adults
Number of subjects: 112

Group type: COMPARATOR
Intervention: Single oral dose of ornidazole, 30 mg/kg for children and 2 g for adults
Number of subjects: 112
Study: 15898859

Group type: EXPERIMENTAL
Intervention: Women with recent onset of BC (63 women)
Number of subjects: 12177

Group type: EXPERIMENTAL
Intervention: Women with longer established onset of BC (181 women)
Number of subjects: 12177

Group type: COMPARATOR
Intervention: Women with no BC (11,933 women)
Number of subjects: 12177
Study: 12075271

Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0
Study: 10568908

Group type: EXPERIMENTAL
Intervention: Corticosteroid application as the study intervention in three trials.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concurrent steroid use allowed in seven trials.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-randomization steroid use instructions specified in 3 of 14 trials where steroids were not part of the intervention.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Steroid dosing during the intervention reported as a secondary outcome measure in four trials.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Free concurrent steroid use during the intervention allowed in 11 RCTs.
Number of subjects: 30
Study: 8733656

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 401

Group type: COMPARATOR
Intervention: Polyvinyl alcohol alone (control)
Number of subjects: 401
Study: 8253823

Group type: EXPERIMENTAL
Intervention: Transient perturbations
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous perturbations
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vision deprivation (eyes-open vs blindfolded)
Number of subjects: 12
Study: 3023712

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 14 mg/kg/d
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclosporine after switch from vehicle
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy
Number of subjects: 21
Study: 29451145

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 114
Study: 27062947

Group type: EXPERIMENTAL
Intervention: Tuina combined with core stability exercises
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tuina alone
Number of subjects: 88
Study: 26168950

Group type: EXPERIMENTAL
Intervention: Augmented premolded earplugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard earplugs (inexpensive, frequently distributed for free at music events)
Number of subjects: 0
Study: 22810757

Group type: EXPERIMENTAL
Intervention: SOC+B12 (pegylated interferon α plus ribavirin plus vitamin B12)
Number of subjects: 94

Group type: COMPARATOR
Intervention: SOC (pegylated interferon α plus ribavirin)
Number of subjects: 94
Study: 21947489

Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure reducer (HIPR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: non-Honan intraocular pressure reducer (non-HIPR)
Number of subjects: 60
Study: 19583558

Group type: EXPERIMENTAL
Intervention: Hormone treatment close to the menopausal transition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 0
Study: 16874014

Group type: EXPERIMENTAL
Intervention: COMBAT protocol (daily celecoxib, 13-cisretinoic acid, metronomic temozolomide, low-dose etoposide)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: COMBAT protocol
Number of subjects: 22
Study: 12642757

Group type: EXPERIMENTAL
Intervention: Mini-intervention (Group A)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Work site visit (Group B)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual care (Group C)
Number of subjects: 164
Study: 10840169

Group type: EXPERIMENTAL
Intervention: Single dose of exogenous testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 7636778

Group type: EXPERIMENTAL
Intervention: naloxone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: mental arithmetic stress
Number of subjects: 20

Group type: COMPARATOR
Intervention: video-watching control task
Number of subjects: 20
Study: 2166452

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM)
Number of subjects: 187

Group type: COMPARATOR
Intervention: im opioids
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) with positive HSV serology
Number of subjects: 187

Group type: COMPARATOR
Intervention: im opioids with positive HSV serology
Number of subjects: 187
Study: 7265455

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (drug group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 100
Study: 31683146

Group type: EXPERIMENTAL
Intervention: Grow When Required Neural Networks (GWRNNs) with dynamic adjustment of activated input connections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GWRNNs with added localisation information to the input data stream
Number of subjects: 0
Study: 30853212

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 27836533

Group type: COMPARATOR
Intervention: Phone reminder
Number of subjects: 749

Group type: COMPARATOR
Intervention: Text reminder
Number of subjects: 749
Study: 25345798

Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 196

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 196
Study: 23806847

Group type: EXPERIMENTAL
Intervention: Oocyte donors (treated)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Natural cycle (control)
Number of subjects: 18
Study: 21741606

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (AT/RT)
Number of subjects: 196
Study: 19875410

Group type: EXPERIMENTAL
Intervention: Eplerenone initiated <7 days after AMI
Number of subjects: 6632

Group type: COMPARATOR
Intervention: Eplerenone initiated >=7 days after AMI
Number of subjects: 6632
Study: 16721750

Group type: EXPERIMENTAL
Intervention: Stimulation ON, patient aware
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stimulation ON, patient blind
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stimulation OFF, patient aware
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stimulation OFF, patient blind
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stimulation ON vs OFF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Interaction of awareness and stimulation condition
Number of subjects: 10
Study: 14660506

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCHO) at 8.5 g CHO x kg(‐1) x day(‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control diet (Con) at 5.4 g CHO x kg(‐1) x day(‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control diet (Con)
Number of subjects: 7
Study: 11763248

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9407678

Group type: EXPERIMENTAL
Intervention: Intermittent bolus epidural morphine (3 mg every 8 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA) with morphine (2 mg bolus, 0.15 mg/h)
Number of subjects: 60
Study: 8143997

Group type: EXPERIMENTAL
Intervention: rectal cisapride (30 mg three times daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: meperidine (1 mg/kg over 3 hours)
Number of subjects: 23
Study: 3341154

Group type: EXPERIMENTAL
Intervention: Systemic steroid treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Surgical removal of nasal polyps
Number of subjects: 53
Study: 31474354

Group type: EXPERIMENTAL
Intervention: Niraparib plus bevacizumab
Number of subjects: 97

Group type: COMPARATOR
Intervention: Single-agent niraparib
Number of subjects: 97
Study: 28418399

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 26163202

Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg) administered with amlodipine (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg) administered with lobeglitazone (0.5 mg)
Number of subjects: 24
Study: 24294746

Group type: EXPERIMENTAL
Intervention: M+M+G (Metronidazole + Metronidazole + Lactobacillus casei var rhamnosus - Lcr 35)
Number of subjects: 60

Group type: COMPARATOR
Intervention: M+M (Metronidazole + Metronidazole)
Number of subjects: 60
Study: 21944122

Group type: EXPERIMENTAL
Intervention: Eraser laser prostate enucleation
Number of subjects: 60

Group type: COMPARATOR
Intervention: bipolar transurethral prostate resection
Number of subjects: 60
Study: 19072600

Group type: EXPERIMENTAL
Intervention: Dog-appeasing pheromone (DAP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16567885

Group type: EXPERIMENTAL
Intervention: Listening to music (Group 2)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Not listening to music (Group 1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 12679426

Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate
Number of subjects: 61
Study: 10783538

Group type: EXPERIMENTAL
Intervention: Selection procedures with negative outcome feedback
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Negative outcome feedback from a racially similar experimenter
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Negative outcome feedback from a racially different experimenter
Number of subjects: 201
Study: 8923550

Group type: EXPERIMENTAL
Intervention: Moving bar stimulus with manipulated retinal-image parameters (2-D stretch/shrinkage, 2-D rotation, 2-D translation)
Number of subjects: 0
Study: 1557933

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 100